Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: red man syndrome

Vancomycin vs TMP/SMX for MRSA – Not the Final Word

Posted on June 12, 2015 by Harald — No Comments ↓

Vancomycin got a bad reputation since the early 90ies when it became clear that it was slow to provide clinical improvement and microbiologic cure in MRSA patients.  It was associated with prolonged bacteremia even when combined with rifampin [1].  And for MSSA, Continue reading Vancomycin vs TMP/SMX for MRSA – Not the Final Word→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email

Like this:

Like Loading...
Posted in Recent Literature, The News, The Viewpoint | Tagged antibiotic blog, bacteremia, ceftaroline, Cubicin, dalbavancin, Dalvance, daptomycin, delta, FDA, interim analysis, linezolid, MRSA, MSSA, nafcillin, non-inferiority, non-inferiority margin, O’Brien-Fleming, Orbactiv, oritavancin, Pocock, red man syndrome, red neck syndrome, TDM, Teflaro, therapeutic drug monitoring, TMP/SMX, vancomycin | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • REGULATORY INTERACTIONS  – 1
  • PK/PD of BIOLOGICALS
  • NANOBODIES FOR AUTOIMMUNE DISEASES
  • About A Prepared Mind – In R&D
  • The 10 x ’20 Initiative – A Retrospective
  • BAFF / APRIL Inhibitors Homing in on IgAN
  • THE UTILITY OF FUTILITY
  • Sulopenem uUTI – Does It Suffice?
  • PUBLICATION OVERACHIEVERS
  • BLUJEPA / Gepotidacin APPROVED FOR UNCOMPLICATED UTI – 1

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Achaogen Allphase Pharma Consulting aminoglycoside antibiotic blog Avelox Bayer Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline Orbactiv oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2025 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d